Seizures are serious complications seen in critically ill patients and can lead to significant morbidity and mortality if the cause is not identified and treated quickly. Uncontrolled seizures can lead to status epilepticus (SE), which is considered a medical emergency. The first-line treatment of seizures is an intravenous (IV) benzodiazepine followed by anticonvulsant therapy. Refractory SE can evolve into a nonconvulsive state requiring IV anesthetics or induction of pharmacological coma. To prevent seizures and further complications in critically ill patients with acute neurological disease or injury, short-term seizure prophylaxis should be considered in certain patients.
Commission on Classification of Terminology, International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22(4):489–501.
2.
LowensteinDBleckTMacdonaldRL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–122.
3.
DeLorenzoRJPellockJMTowneAR. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995;12(4):316–328.
4.
PenberthyLTTowneAGarnettLK. Estimating the economic burden of status epilepticus to the health care system. Seizure. 2005;14(1):46–51.
5.
DeLorenzoRJ. Epidemiology and clinical presentation of status epilepticus. Adv Neurol. 2006;97:199–215.
6.
ChinRFNevilleBGPeckhamC. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective, population-based study. Lancet. 2006;368(9531):222–229.
7.
HauserWA. Status epilepticus: epidemiologic considerations. Neurology. 1990;40(5 suppl 2):9–13.
8.
DeLorenzoRJHauserWATowneAR. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–1035.
9.
LowensteinDHAlldredgeBK. Status epilepticus. N Engl J Med. 1998;338(14):970–976.
10.
PitkanenA. Efficacy of current antiepileptics to prevent neurodegredation in epilepsy models. Epilepsy Res. 2002;50(1-2):141–160.
11.
JonesDMEsmaeilNMarenS. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res. 2002;50(3):301–312.
12.
Brooks-KayalAShumateMRikhterT. Selective changes in single cell GABA A receptor subunit expression and function in temporal lobe epilepsy. Nat Med. 1998;4(10):1166–1172.
13.
WasterlainCGFujikawaDGPenixL. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia. 1993;34(suppl 1):S37–S53.
14.
LothmanE. The biochemical basis and pathophysiology of status epilepticus. Neurology. 1990;40(5 suppl 2):13–23.
15.
AlldredgeBKLowensteinDHSimonRP. Seizures associated with recreational drug abuse. Neurology. 1989;39(8):1037–1039.
16.
ThabetFAl MaghrabiMAl BarraqA. Cefepime-induced nonconvulsive status epilepticus: case report and review. Neurocrit Care. 2009;10(3):347–351.
17.
SprietIGovensJMeerssemanW. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007;41(7):1130–1136.
18.
LegrielSMourvillierBBeleN. Outcomes in 140 critically ill patients with status epilepticus. Intensive Care Med. 2008;34(3):476–480.
19.
RossettiAOBromfieldEB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol. 2005;54(1):34–38.
20.
TreimanDMMeyersPDWaltonNY. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med. 1998;339(12):792–798.
21.
LeppikIEDerivanATHomanRW. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249(11):1452–1454.
22.
FountainNBAdamsRE. Midazolam treatment of acute and refractory status epilepticus. Clin Neuropharmacol. 1999;22(5):261–267.
23.
TowneARDeLorenzoRJ. Use of intramuscular midazolam for status epilepticus. J Emerg Med. 1999;17(2):323–328.
24.
ScottRCBesagFMBoydSG. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia. 1998;39(3):290–294.
25.
KendallJLReynoldsMGoldbergR. Intranasal midazolam in patients with status epilepticus. Ann Emerg Med. 1997;29(3):415–417.
26.
TemkinNRDikmenSSWilenskyAJ. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990;323(8):497–502.
27.
BerningSBoesebeckFvan BaalenA. Intravenous levetiracetam as treatment for status epilepticus. J Neurol. 2009;256(10):1634–1642.
AndersonGSPakCDoaneKW. Revised winter-tozer equation for normalized phenytoin concentrations in trauma and elderly patients with hypoalbuminemia. Ann Pharmacother. 1997;31(3):279–284.
PryorFMGidalBRamsayRE. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. Epilepsia. 2001;42(2):245–250.
33.
MazaratiAMBaldwinRASankarR. Time-dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res. 1998;814(1-2):179–185.
34.
LimdiNAShimpiAVFaughtE. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology. 2005;64(2):353–355.
35.
PetersCNPohlmann-EdenB. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus-experience in 102 adult patients. Seizure. 2005;14(3):164–169.
36.
HodgesBMMazurJE. Intravenous valproate in status epilepticus. Ann Pharmacother. 2001;35(11):1465–1470.
37.
UberallMATrollmanRWundsiedlerU. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology. 2000;54(11):2188–2180.
38.
AgarwalPKumarNChandraR. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16(6):527–532.
39.
GiladRIzkovitzNDabbyR. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand. 2008;118(5):296–300.
40.
LheureuxPEPenalozaAZahirS. Science review: carnitine in the treatment of valproic acid-induced toxicity—what is the evidence?Crit Care. 2005;9(5):431–440.
41.
LynchBALambengNNockaK. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861–9866.
42.
RueggSNaegelinYHardmeierM. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav. 2008;12(3):477–480.
43.
NauKMDivertieGDValentinoAK. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care. 2009;11(1):34–37.
44.
RossettiAOBromfieldEB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 2006;8(3):651–654.
45.
Au YeungSCEnsomMH. Phenytoin and enteral feedings: does evidence support an interaction?Ann Pharmacother. 2000;34(7-8):896–905.
46.
Clark-SchmidtALGarnettWRLoweDR. Loss of carbamazepine suspension through nasogastric feeding tubes. Am J Hosp Pharm. 1990;47(9):2034–2037.
47.
FerrellPBMcLeodHL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–1546.
48.
KuehnBM. FDA: epilepsy drugs may carry skin risks for Asians. JAMA. 2008;300(24):2845.
49.
HungCCLinCJChenCC. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit. 2004;26(5):534–540.
50.
MayerSAClaassenJLokinJ. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59(2):205–210.
51.
DrislaneFWLopezMRBlumAS. Detection and treatment of refractory status epilepticus in the intensive care unit. J Clin Neurophysiol. 2008;25(4):181–186.
52.
ClaassenJHirschLJEmersonRG. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systemic review. Epilepsia. 2002;43(2):146–153.
53.
BleckTP. Refractory status epilepticus. Curr Opin Crit Care. 2005;11(2):117–120.
54.
MarikPEVaronJ. The management of status epilepticus. Chest. 2004;126(2):582–591.
55.
KalviainenRErikssonKParviainenI. Refractory generalized convulsive status epilepticus—a guide to treatment. CNS Drugs. 2005;19:759–768.
56.
ParentJMLowensteinDH. Treatment of refractory generalized status epilepticus with continuous infusion of midazolam. Neurology. 1994;44(10):1837–1840.
57.
ClaassenJHirschLJEmersonRG. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. Neurology. 2001;57(6):1036–1042.
58.
UlviHYoldasTMungenB. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci. 2002;23(4):177–182.
59.
NantokuDKSinhaS. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology. 2000;54(6):1366–1368.
60.
JonesPJWangYSmithMD. Hydroxyamide analogs of propofol exhibit state-dependent block of sodium channels in hippocampal neurons: implications for anticonvulsant activity. J Pharmacol Exp Ther. 2007;320(2):828–836.
61.
KangTM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother. 2002;36(9):1453–1456.
62.
IyerVNHoelRRabinsteinAA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med. 2009;37(12):3024–3030.
63.
FongJJSylviaLRuthazerR. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med. 2008;36(8):2281–2287.
64.
SneydJR. Propofol and epilepsy. Br J Anaesthesia. 1999;82(6):168–169.
65.
Van NessPC. Pentobarbital and EEG burst suppression in treatment of status epilepticus refractory to benzodiazepines and phenytoin. Epilepsia. 1990;31(1):611–617.
66.
KrishnamurthyKBDrislaneFW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia. 1999;40(6):759–762.
67.
ParviainenIUusaroAKalviainenR. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology. 2002;59(8):1249–1251.
PatelNCLandanIRLevinJ. The use of levetiracetam in refractory status epilepticus. Seizure. 2006;15(3):137–141.
70.
UgesJWFvan HuizenMDEngelsmanJ. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. Epilepsia. 2009;50(3):415–421.
71.
BorrisDJBertramEHKapurJ. Ketamine controls prolonged status epilepticus. Epilepsy Res. 2000;42(2-3):117–122.
72.
PrussHHoltkampM. Ketamine successfully terminates malignant status epilepticus. Epilepsy Res. 2008;82(2-3):219–222.
73.
ShethRDGidalBE. Refractory status epilepticus: response to ketamine. Neurology. 1998;51(6):1765–1766.
74.
UboguEESagarSMLernerAJ. Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav. 2003;4(1):70–75.
75.
BleckTPQuiggMSNathanBR. Electroencephalographic effects of ketamine treatment for refractory status epilepticus. Epilepsia. 2002;43(suppl 1):282.
76.
TowneARGarnettLKWaterhouseEJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60(2):332–334.
TilzCReschRHoferT. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia. 2010;51(2):316–317.
79.
KellinghausCBerningSBesselmannM. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009;14(2):429–431.
80.
ChumnanvejSDunnIFKimDH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery. 2007;60(1):99–102.
81.
RosengartAJHuoDTolentinoJ. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg. 2007;107(2):253–260.
82.
NaidechAMKreiterKTJanjuaN. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583–587.
83.
BedersonJBConnollyESBatjerHH. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40(3):994–1025.
84.
MolyneuxAJKerrRSYuLM. International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488):809–817.
85.
VespaPMO’PhelanKShahM. Acute seizures after intracerebral hemorrhage. Neurology. 2003;60(9):1441–1446.
86.
PasseroSRocchiRRossiS. Seizures after spontaneous supratentorial intracerebral hemorrhage. Epilepsia. 2003;43(10):1175–1180.
87.
MesseSRSansingLHCuccchiaraBL. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. Neurocrit Care. 2009;11(1):38–44.
88.
NaidechAMGargRKLieblingS. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke. 2009;40(12):3810–3815.
89.
Tremont-LukatsIWRatilalBOArmstrongT. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev. 2008;(2):CD004424.
90.
SirvenJIWingerchukDMDrazkowskiJF. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc. 2004;79(12):1489–1494.
91.
AhmedIReichenbergJLucasA. Erythema multiforme associated with phenytoin and cranial radiation therapy: A report of three patients and review of the literature. Int J Dermatol. 2004;43(1):67–73.
92.
GrossmanSAHochbergFFisherJ. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol. 1998;42(2):118–126.
93.
MilliganTAHurwitzSBromfieldEB. Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology. 2008;71(9):665–669.
94.
LinCLDumontASLieuAS. Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99(6):978–985.
95.
BergerARLiptonRBLesserML. Early seizures following intracerebral hemorrhage: implications for therapy. Neurology. 1988;38(9):1363–1365.
96.
BroderickJPAdamsHPJrBarsanW. Guidelines for the management of spontaneous intracerebral hemorrhage. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke. 1999;30(4):905–915.
97.
GlantzMColeBForsythP. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors—report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;54(10):1886–1893.
98.
VechtCvan BreemenM. Optimizing therapy of seizures in specific clinical situations. Neurology. 2006;67(12 suppl 4):S10–S13.
99.
LiuKCBhardwajA. Use of prophylactic anticonvulsants in neurologic critical care: a critical appraisal. Neurocrit Care. 2007;7(2):175–184.
100.
RatilalBCostaJSampaioC. Anticonvulsants for preventing seizures in patients with chronic subdural haematoma. Cochrane Database Syst Rev. 2005;(3):CD004893.
101.
SwanJWoodE. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev. 2010;(1):CD005398.
102.
ShahDHusainAM. Utility of levetiracetam in patients with subarachnoid hemorrhage. S\eizure. 2009;18(10):676–679.
